Literature DB >> 29202965

Role of medical therapy in the management of deep rectovaginal endometriosis.

Paolo Vercellini1, Laura Buggio2, Edgardo Somigliana2.   

Abstract

Defining whether medical therapy is effective in women with deep rectovaginal endometriosis and in which circumstances it can be considered an alternative to surgery is important for patients and physicians. Numerous observational and some randomized controlled studies demonstrated that different hormonal drugs improved pain and other symptoms in approximately two-thirds of women with deep rectovaginal endometriosis. Because major differences in the effect size of various compounds were not observed, much importance should be given to safety, tolerability, and cost of medications when counseling patients. Progestins seem to offer the best therapeutic balance when long-term treatments are planned. Women should be informed that hormonal drugs control but do not cure endometriosis and that, to avoid surgery, they should be used for years. Medical therapy is not an alternative to surgery in women with hydronephrosis, severe subocclusive bowel symptoms, and in those wishing a natural conception. A progestin should systematically be chosen as a comparator in future randomized trials on novel medications for deep endometriosis. In the meantime, the use of existing drugs should be optimized, and medical and surgical treatments could be viewed as subsequent stages of a stepwise approach. In general, there is no absolute "best" choice, and women must be thoroughly informed of potential benefits, potential harms, and costs of different therapeutic options and allowed to choose what they deem is better for them.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dysmenorrhea; dyspareunia; endometriosis; medical therapy; pelvic pain

Mesh:

Substances:

Year:  2017        PMID: 29202965     DOI: 10.1016/j.fertnstert.2017.08.038

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  Carbon dioxide (CO2) laser ablation of symptomatic vaginal endometriosis: a pilot study.

Authors:  Laura Buggio; Ermelinda Monti; Carlo Liverani; Maria Pina Frattaruolo; Dhouha Dridi; Edgardo Somigliana
Journal:  Lasers Med Sci       Date:  2020-10-16       Impact factor: 3.161

Review 2.  GnRH Antagonists with or without Add-Back Therapy: A New Alternative in the Management of Endometriosis?

Authors:  Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

3.  Rectosigmoid endometriosis: Diagnostic pitfalls and management - A case report.

Authors:  Athanasios Piachas; Panagiotis Smyrnis; Andreas Tooulias
Journal:  Clin Case Rep       Date:  2022-02-20

4.  The multistep process of vaginal cancer arising from deep infiltrating endometriosis: a case report.

Authors:  Jee Hyun Kim; Seung Hun Song; Gwangil Kim; Kyoung Ah Kim; Woo Ram Kim
Journal:  BMC Womens Health       Date:  2021-07-12       Impact factor: 2.809

5.  Daily Vaginal Application of Dienogest (Visanne©) for 3 Months in Symptomatic Deeply Infiltrating Rectovaginal Endometriosis: A Possible New Treatment Approach?

Authors:  Andreas D Ebert
Journal:  Case Rep Obstet Gynecol       Date:  2018-05-10

6.  Magnetic resonance imaging presentation of deep infiltrating endometriosis nodules before and after pregnancy: A case series.

Authors:  Anne Elodie Millischer; Louis Marcellin; Pietro Santulli; Chloe Maignien; Mathilde Bourdon; Bruno Borghese; François Goffinet; Charles Chapron
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

Review 7.  Bowel Endometriosis: Current Perspectives on Diagnosis and Treatment.

Authors:  Nassir Habib; Gabriele Centini; Lucia Lazzeri; Nicola Amoruso; Lionel El Khoury; Errico Zupi; Karolina Afors
Journal:  Int J Womens Health       Date:  2020-01-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.